Chelation Therapy (page 3)
Olwin and others suggested a rationale for the use of EDTA, magnesium, and heparin in
combination to achieve lasting cardiac revitalization. The Rozema EDTA chelation protocol
also commented on a number of other substances for suitable co-administration with EDTA,
including magnesium (as chloride or sulfate), sodium bicarbonate, local anesthetics, heparin,
ascorbic acid (vitamin C), B vitamins, and minerals. A number of chelating agents were
reviewed and found to compare negatively with EDTA in respect to safety and benefit. Yet
EDTA chelation therapy has yet to receive widespread acceptance by the clinical community.
Although it has not been subjected to vast numbers of clinical trials, two meta-analyses
suggest EDTA chelation therapy benefits cardiovascular symptoms in more than four out of
five patients. In 1993, Chappell and Stahl published an analysis of data on 22,765 patients,
compiled from 19 published clinical studies. They found a correlation coefficient of 87 percent
between EDTA therapy and improved cardiovascular symptomatology based on objective
testing. Subsequently, they obtained unpublished “file drawer” data on 1,241 objectively-
sorted patients from 32 clinicians. From this approach they obtained a correlation coefficient of
88 percent further building the case for cardiovascular benefit from EDTA chelation.
EDTA chelation therapy may eventually be proven a viable alternative to bypass or
angioplasty. Danish physicians Hancke and Flytlie reported retrospectively on 470 patients
with atherosclerosis. Of 65 patients awaiting bypass surgery and subjected to chelation, the
vast majority showed clinical improvement; when chelation was completed only seven still
required bypass. Of 27 patients previously scheduled for leg amputation, only three required
surgery following courses of chelation therapy. These enticing results from EDTA chelation
invite a well-controlled comparison of chelation and revascularization, with the hope of being
able to replace surgical revascularization techniques or to use chelation as an adjunct to these
interventions.
From an article by Parris M. Kidd, Ph.D.
combination to achieve lasting cardiac revitalization. The Rozema EDTA chelation protocol
also commented on a number of other substances for suitable co-administration with EDTA,
including magnesium (as chloride or sulfate), sodium bicarbonate, local anesthetics, heparin,
ascorbic acid (vitamin C), B vitamins, and minerals. A number of chelating agents were
reviewed and found to compare negatively with EDTA in respect to safety and benefit. Yet
EDTA chelation therapy has yet to receive widespread acceptance by the clinical community.
Although it has not been subjected to vast numbers of clinical trials, two meta-analyses
suggest EDTA chelation therapy benefits cardiovascular symptoms in more than four out of
five patients. In 1993, Chappell and Stahl published an analysis of data on 22,765 patients,
compiled from 19 published clinical studies. They found a correlation coefficient of 87 percent
between EDTA therapy and improved cardiovascular symptomatology based on objective
testing. Subsequently, they obtained unpublished “file drawer” data on 1,241 objectively-
sorted patients from 32 clinicians. From this approach they obtained a correlation coefficient of
88 percent further building the case for cardiovascular benefit from EDTA chelation.
EDTA chelation therapy may eventually be proven a viable alternative to bypass or
angioplasty. Danish physicians Hancke and Flytlie reported retrospectively on 470 patients
with atherosclerosis. Of 65 patients awaiting bypass surgery and subjected to chelation, the
vast majority showed clinical improvement; when chelation was completed only seven still
required bypass. Of 27 patients previously scheduled for leg amputation, only three required
surgery following courses of chelation therapy. These enticing results from EDTA chelation
invite a well-controlled comparison of chelation and revascularization, with the hope of being
able to replace surgical revascularization techniques or to use chelation as an adjunct to these
interventions.
From an article by Parris M. Kidd, Ph.D.
| Copyright © 2003-2004 Boulder Natural Medicine Clinic, LLC. All rights reserved. Email : info@bouldernatural.com Phone: 303.447.1339 |
| Boulder Natural Medicine Clinic, LLC |
 |
| |
 |
| |
 |
| |
 |
 | |  | |  | |  | |  | |  |
